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Abstract
Objectives: Treatment of osteoarthritis (OA) using autologous conditioned serum (ACS) has become in recent 
years an alternative to consider in  the approach of the degenerative joint disease of the knee. There is no support 
in the literature for the use of ACS for the treatment of OA of the temporomandibular joint (TMJ), although the 
promising results obtained in human patients with knee joint disease as well as in animal studies are opening the 
way for its use at the TMJ. The aim of this paper is to conduct a review of the published literature regarding the 
use of the ACS for the treatment of OA in humans, considering the level of scientific evidence, and following the 
principles of the evidence-based medicine and dentistry.
Material and Methods: A PubMed-MEDLINE search was carried out of articles published between 1980 and 2011. 
After an initial search, a total of 102 articles were obtained, followed by a selection of the most relevant articles 
according to the topic; a total of 8 articles were selected, which were stratified according to their level of scientific 
evidence using SORT criteria (Strength of Recommendation Taxonomy).
Results: At the time of this review, there is no available literature referring the use of ACS at the TMJ. However, the 
use of the ACS in other joints is well documented, both experimentally and clinically, in humans and animals. The 
reviewed articles, with a level of evidence 1 and 2 according to the SORT criteria, have generally promising results.
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Discussion and Conclusions: The use of ACS in the treatment of OA in joints other than the TMJ, is endorsed by the 
level of evidence found in the literature, which opens the door to future studies to determine the feasibility of the use 
of the ACS in the treatment of degenerative OA that affects TMJ.
Key words: Osteoarthritis, temporomandibular joint, autologous conditioned serum.
Introduction
Osteoarthritis (OA) of the temporomandibular joint 
(TMJ) is a common pathology. It appears as a degen-
erative, progressive, slow evolution pathology, which 
affects TMJ, both hard and soft tissues. OA is associ-
ated to mechanical overload of the joint caused by mi-
cro or macro trauma, secondary to the presence of other 
pathological process, such as a disc disease, or associ-
ated to a systemic condition of the patient, in the case 
of rheumatoid arthritis (1). OA is a degenerative disease 
associated with inflammatory changes of the TMJ. Al-
though associated with all age groups, there is a higher 
incidence in patients of about 40 years old, with a pre-
dilection for women. Radiographic changes of the TMJ 
associated with OA are present in 17% of patients over 
65 years; 50% of those have a mild to moderate degree 
(or worse) level of pain and dysfunction in their jaw, 
which would reduce the 17% figure in individuals over 
65 years of age to 8.5% with substantial clinical symp-
toms (1). It is no clear what the prevalence of TMJ OA is 
in younger  population.
The clinical signs of OA include pain, decreased jaw 
mobility and crepitus in mouth opening (1). OA appears 
as changes in the surface of the joint, affected by ero-
sion, sclerosis, thinning and the appearance of unilat-
eral osteophytes, although it can be seen affecting both 
TMJs (2). These changes in the articular surfaces are 
joined by changes in the synovial fluid, as increased lev-
els of the inflammatory mediators, such as interleukin 
(IL) 1B, tumor necrosis factor α and IL 6 (1).
Treatment of symptomatic OA is primarily based on a re-
strictive therapy of joint movements, the use of drugs such 
as nonsteroidal antiinflammatory drugs (NSAIDs) and 
cyclooxygenase-2 (COX-2) inhibitors, the use of occlusal 
splints, thermotherapy, or minimally invasive techniques 
such as arthrocentesis. The use of invasive techniques 
as the arthroplasty is recommended only when all other 
treatment options are depleted. Pharmacological treat-
ment of OA does not prevent the progression of the dis-
ease, although it has been shown to significantly reduce 
the associated symptoms (3). Additionally, prolonged 
use of these drugs is associated with significant side ef-
fects such as increased risk of gastrointestinal bleeding 
and cardiovascular ischemia (3). Non-symptomatic OA 
should be monitored by the specialist, but it doesn’t re-
quired symptomatic treatment most of the time.
In recent years, research for the treatment of OA has 
been focused on the use of drugs that not just improve 
the patient’s symptoms, but also be able to alter the de-
velopment of OA, and therefore delay or even prevent 
the need for invasive techniques for treatment. Glu-
cosamine sulfate and chondroitin sulfate have been the 
most studied. It has been shown that, used in combi-
nation, have been effective in reducing symptoms in a 
subgroup of patients with moderate to severe pain in the 
knee joint (4). Despite this, their role as modifiers of the 
progression of OA is still controversial.
The balance of the cytokines, along with their recep-
tors and receptor antagonist are crucial, not just for the 
initiation and progression of OA, but also in the clini-
cal expression of this condition (5); therefore, cytokines 
have been proposed as targets in the therapy of OA. 
Interleukin 1β (IL-1β), a proinflammatory cytokine, 
seems to play an important role in the production of col-
lagenase and prostaglandins by releasing a cascade of 
inflammatory and catabolic events, resulting in a reduc-
tion in the synthesis of proteoglycans and cartilage-spe-
cific collagens (6). The number of receptors for IL-1β is 
significantly increased in chondrocytes and synovial fi-
broblasts in OA (7). The natural inhibitor of IL-1β, IL-1β 
receptor antagonist (IL-1βRa) may have the potential to 
limit intraarticular action of IL-1β, and thus, control the 
development of the disease. In an animal model, stimu-
lation “in vivo” of IL-1βRa by gene therapy resulted in 
a significant improvement in clinical parameters of pain 
and disease development, maintenance of articular car-
tilage as well as beneficial effects in the synovial mem-
brane and articular cartilage at histological levels(8).
Autologous conditioned serum (ACS) was developed in 
the mid 90’s, with the idea of obtaining an injectable 
material enriched with IL-1βRa, to be used as a treat-
ment for OA (9). Meijer et al. (10) showed that, follow-
ing the blood exposure to glass beads, a rapid increase 
in the synthesis of various inflammatory cytokines, 
including IL-1βRa, is obtained. ACS is prepared by 
taking a blood sample and incubating it in a syringe, 
into which CrSO4-coated glass beads are disposed. It 
has been shown that the synthesis of IL-1βRa, as well 
as other anti-inflammatory cytokines such as IL-4, IL-
10 and IL-13 (3) is stimulated through this procedure. 
Currently, the ACS is marketed under the name of 
Orthokine ® (Orthogen, Düsseldorf, Germany). ACS 
theraphy appears as an option in the treatment of non-
restrictive OA, in terms of its evolution and associated 
pain. Nevertheless, surgery should be considered as a 
treatment option for severe, restrictive OA.
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The aim of this paper is to conduct a review of pub-
lished literature regarding use of the SAC in the treat-
ment of OA in humans, taking into account the level 
of scientific evidence, and following the principles of 
based-evidence medicine and dentistry.
Material and Methods
A PubMed-MEDLINE search of articles published be-
tween 1980 and 2011 was conducted. In an initial ap-
proach, the search terms “Osteoarthritis,” “TMJ”, “Au-
tologous Conditioned Serum” and “Orthokine” were 
used, the first of them included in the MeSH (Medical 
Subject Heading) data base. Search was limited to “in 
vitro”, animal and human studies, and articles written in 
English. The terms were then merged in a second search 
using the Boolean operator “AND”, obtaining the arti-
cles that included two or more of the search terms. The 
authors analyzed the searched articles  to verify their 
relevance with the topic under study. The irrelevant 
articles were discarded. Next, the authors stratified the 
items according to their level of scientific evidence, us-
ing the SORT criteria (Strength of Recommendation 
Taxonomy) (Tables 1,2,3). The authors then compared 
their results, in case of disagreement the results were 
discussed. Subsequently, according to the level of scien-
tific evidence of the articles reviewed, a recommenda-
tion level was declared in favor of, or against the use of 
ACS in the treatment of OA.
Table 1. SORT Criteria (Strength of Recommendation Taxonomy).
Strength of Recom-
mendation
Definition
A Recommendation based on consistent and good-quality, patient-oriented 
evidence (1)
B Recommendation based on inconsistent or limited-quality, patient-
oriented evidence (1)
C Recommendation based on consensus, usual practice, opinion, disease-
oriented evidence (2), or on case series for studies of diagnosis, treat-
ment, prevention or screening
(1) Patient-oriented evidence considers the following objectives: reduction of mortality and morbidity, im-
provement of the symptoms, better quality of life, reduced costs.
(2) Disease-oriented evidence comprises intermediate, histopathologic, physiologic and other surrogate or 
potentially useful results for improving the patient’s quality of life (blood sugar, blood pressure, etc.) that may 
or not reflect the patient’s actual improvement.
?
Study quality Diagnosis Treatment/prevention/ 
screening 
 Prognosis 
Level 1:  
Good-quality, patient-
oriented evidence 
•SR/meta-analysis of high- 
quality studies 
•High-quality diagnostic 
cohort study 
•SR/meta-analysis of RCTs 
with consistent findings 
•High quality individual RCT 
•All or none studies. 
•SR/meta-analysis of good- 
quality cohort studies 
•Prospective cohort study 
with good follow-up 
Level 2:  
Limited- quality, patient-
oriented evidence 
•SR/meta-analysis of low- 
quality studies or studies with 
inconsistent findings 
•Cohort study or low- quality 
case control study 
•SR/meta-analysis of low-
quality clinical trials or of 
studies with inconsistent 
findings
•Low-quality clinical trial 
•Cohort study 
•Case control study 
•SR/meta-analysis of lower- 
quality cohort studies or with 
inconsistent results 
•Retrospective cohort study 
or prospective cohort study 
with poor follow-up 
•Case-control study 
•Case series 
Level 3: 
Other evidence 
• Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease- 
oriented evidence, or case series to study diagnosis, treatment, prevention or screening 
Table 2. Levels of scientific evidence.
Abbreviations: SR = systematic review; RCT = randomized clinical trial.
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Authors and year Journal Scientific evidence
Meijer et al. (2003) (10) Inflamm Res Level 1
Baltzer et al. (2009) (9) Osteoarthritis Cartilage Level 1
Rutgers et al. (2010) (7) Arthritis Res Ther Level 1
Wright-Carpenter (2004) (13) Int J Sports Med Level 2
Frisbie et al. (2007) (11) Am J Vet Res Level 2
Wehling el al. (2007) (14) Biodrugs Level 2
Yang et al. (2008) (3) Osteoarthritis Cartilage Level 2
Darabos et al. (2009) (15) Int Orthop Level 2
Table 3. Level 1 and 2 studies that analyze the use of ACS in the treatment of OA of the TMJ.
Abbreviations: ACS= autologous conditioned serum; OA= Osteoarthritis; TMJ: temporoman-
dibular joint.
Results
The initial PubMed-MEDLINE search provided a total 
of 43891 articles for the term “Osteoarthritis”, 20440 
articles on “TMJ”, 102 for the term “Autologous Con-
ditioned Serum” and 6 items on “Orthokine”. After the 
second electronic search, which merged keywords, a 
total of 102 articles with two or more of the terms used 
were obtained.
Articles with significant methodological errors such as 
an insufficient patient sample, inadequate sample selec-
tion criteria, imprecise definition of the study groups, 
inadequate description of the analyzed variables, or in-
complete and/or inadequate presentation of the results 
obtained in the study were discarded. 
A total of 23 articles with relevance to our review were 
obtained after the first analysis. These articles were 
stratified by their level of scientific evidence, using the 
SORT criteria, discarding those articles with a level of 
evidence 3. A total of 8 articles were obtained, three 
articles with a level of evidence 1 and the remaining five 
with a level of scientific evidence of 2. None of the ar-
ticles reviewed referred to the use of ACS for the treat-
ment of OA of the TMJ.
In accordance with the principles of evidence-based 
dentistry, the analysis of the results revealed a type A 
recommendation for the use of the ACS in the treatment 
of OA, even with a lack of specific studies evaluating its 
use at the TMJ. 
Discussion
It is believed that IL-1β plays a role in the cartilage de-
struction, inherent to articular pathologies such as OA. 
It has been suggested, both in experimental and animal 
models of OA, that IL-1βRa could have beneficial ef-
fects associated to the symptoms and structural changes 
shown in OA. The use of the ACS as a source of IL-1βRa 
appears to achieved good results in patients with synovial 
joints OA, like the knee, although these results may not 
apply in a straightforward manner to the OA of the TMJ, 
because to their unique anatomy and physiology. Any-
way, these results serve as a reference when determining 
the efficacy of the ACS in the TMJ treatment.
Baltzer et al. (9) and Yang et al. (3) indicated that use 
of the ACS is safe and effective in the treatment of OA 
of the knee joint, and that its therapeutic effects may 
persist for at least two years. Baltzer et al. (9) explained 
that, although the mechanism through which it is possi-
ble to obtain an increase in the concentration of IL-1βRa 
joint level is not entirely clear, ACS is a very reproduc-
ible technique, with predictable effects. The clinical 
effects observed can be explained by a multitude of 
active therapeutic molecules with synergistic activity, 
although their persistence over time is not clear.
The therapeutic preparation known by the trade name 
of Orthokine®, is based on the stimulation of the in-
creased concentrations of inflammatory cytokines, such 
as IL-1βRa, inside the joint complex. The technique in-
volves perform of a blood culture of the patient using 
a syringe that contains CrSO4 surface-treated glass 
spheres. After a 24 hours incubation at 37 °C, a clear-
ance by centrifugation of the sample is made. The ACS, 
now enriched with IL-1βRa, IL-4 and IL-10, is injected 
inside the affected joint (10).
Exposure of the patient’s blood to the CrSO4 surface-
treated glass spheres leads to a vigorous and rapid in-
crease in the concentration of various inflammatory 
cytokines, including IL-1βRa, IL-4 and IL-10 (10). An 
increase up to 140 times the concentration of IL-1βRa 
during incubation for 24 hours can be detected (10,11). 
However, no increased levels of pro-inflammatory cy-
tokines such as IL-1β or tumor necrosis factor α (TNF-α) 
were detected in the same period of incubation (10).
The use of ACS therapy has been studied in a profuse 
way in synovial joints such as the knee. Studies con-
cerning the treatment of OA are especially prolific in 
horses, because it is considered a high incidence disease 
among equines, with a great economic importance in 
this industry.
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In a study of Frisbie et al. (11), 16 horses with arthro-
scopic-induced OA of the medial carpal joint were 
treated, eight of them (experimental group) by intra-
articular injection of ACS previously obtained from a 
blood sample, and the remaining eight subjects (control 
group) using an intra-articular injection of phosphate 
buffered saline (PBS), once a week for 5 weeks. The 
joints treated with ACS showed significant clinical im-
provement, compared with those in the control group. 
Moreover, the joints treated with the ACS showed a sig-
nificant decrease in synovial membrane hyperplasia, as 
well as a decrease level of intraarticular bleeding, with 
no statistical significance.
The analyzed literature is limited to the treatment of 
the OA of the knee joint with the ACS technique in hu-
mans. Baltzer et al. (9), in a prospective, randomized, 
double blind study, of 376 individuals with knee joint 
OA, reported that, patients treated by ACS showed sig-
nificant improvements in their quality of life compared 
to those in who was performed intra-articular injections 
of hyaluronic acid or placebo. The authors reported that 
treatment with the ACS is safe, having therapeutic ef-
fects over the main clinical parameters associated with 
OA of the knee joint. The authors added that treatment 
is effective in OA patients with  low or medium pain 
level, measured by visual analogue scale (VAS); the 
authors also reported positive results in patients with 
severe pain, although they recommend not extrapolate 
the results to all OA patients.
Yang et al. (3), in a multicenter, prospective, double-blind 
study, evaluated 167 randomized patients who received 
6 intra-articular injections, ACS for patients in the ex-
perimental group or saline solution for those included in 
the control group. After carrying out controls at 3, 6, 9 
and 12 months, statistically significant improvements in 
both groups with respect to the values obtained at base-
line were observed. Authors showed that symptoms at 
3, 6, 9 and 12 months reported by patients treated with 
the ACS would have better clinical outcomes than those 
treated with placebo, but clarify that the statistical dif-
ference is small. The authors reported the occurrence of 
complications associated with intra-articular injection 
of the ACS, as in a case of septic arthritis caused by the 
injection, and another case in which a patient suffered 
repeated inflammatory reactions after 3 injections, after 
which was withdrawn from the study.
The main problem encountered when the transpose of 
these results is performed into the daily practice of the 
treatment of OA of the TMJ, is the lack of specific re-
search in our area. All the analyzed studies are the re-
sult of the work of scientific teams involved in the treat-
ment of OA of large synovial joints, such as the knee. 
The physiology and anatomy of the TMJ, a bilateral bi-
condylar synovial joint, with significant differences in 
other body joints, so that although the results obtained 
in other joints are easily extrapolated to the TMJ, these 
are not specific, and variations may exist in the clinical 
and statistical results. Zhang et al (12), make a histologi-
cal evaluation in 24 New Zealand rabbits, performing 
a partial perforation of the articular disc, thus induc-
ing OA at both TMJs. The intra articular injection of 50 
g of human IL-1βRa solution with 50 μl of saline into 
the right TMJ (experimental group) and 50 μl of saline 
into the left TMJ (control group) was performed. Ani-
mals were sacrificed at 12 and 24 weeks after injection, 
histological evaluation of the mandibular condyles was 
performed, followed by a genetic chain reaction (PCR) 
study. Histologically, fibrocartilage articular thickening 
in the experimental side and a considerable increase in 
the number of chondrocytes in comparison with those 
found in the control side was observed at both 12 and at 
24 weeks; Control side showed a considerable increase 
in the histological changes associated with degenerative 
OA after 24 weeks. No significant differences in the ex-
pression of TNF-α between both groups was observed, 
although the expression of collagen type II was greater 
in the experimental side, so they conclude that the activ-
ity spectrum of TNF- α and IL-1 in OA may overlap, the 
application of recombinant IL-1βRa does not suppress 
the expression of TNF-α.
Under normal conditions, the balance between differ-
ent anabolic and catabolic factors maintains articular 
cartilage homeostasis. However, in OA this balance 
tilts in favor of the destruction of the cartilage matrix. 
It has been shown that IL-1 stimulates the secretion of 
catabolic enzymes, while suppressing the synthesis of 
matrix proteins, including collagen type II. Therefore, 
it would be essential in the process of repair of articu-
lar cartilage overexpression the suppression of catabolic 
factors, the stimulation of secretion of anabolic factors. 
For this reason, the use of IL-1βRa obtained by the ACS 
therapy is presented as a tangible alternative in OA 
treatment.
Conclusion
Studies to evaluate a possible application of the ACS 
technique in the treatment of OA of the TMJ are required. 
The use of ACS in the treatment of OA is supported by 
the level of evidence found in the literature in this review, 
may opens the door to future studies to determine the 
feasibility of its use in the treatment of degenerative OA 
affecting the TMJ.
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